Dhruv S. Kazi, MD, MSc, MS; Joanne Penko, MS, MPH; Daniel A. Ollendorf, PhD; Pamela G. Coxson, PhD; Kirsten Bibbins-Domingo, PhD, MD, MAS
Disclaimer: Dr. Ollendorf is an employee of the Institute for Clinical and Economic Review, an independent organization that evaluates the evidence on the value of health care interventions that is funded by grants from the Laura and John Arnold Foundation, Blue Shield of California Foundation, and the California Healthcare Foundation. The organization's annual summit is supported by dues from Aetna, America's Health Insurance Plans, Anthem, Blue Shield of California, CVS Caremark, Express Scripts, Harvard Pilgrim Health Care, OmedaRx, United Healthcare, Kaiser Permanente, Premera Blue Cross, AstraZeneca, Genentech, GlaxoSmithKline, Johnson & Johnson, Merck, National Pharmaceutical Council, Takeda, Pfizer, Novartis, Eli Lilly, and Humana. Research materials from the Framingham Heart Study cohort and Framingham Offspring Study were obtained from the National Heart, Lung, and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center. This article does not necessarily reflect the opinions or views of the Framingham Heart Study cohort, Framingham Offspring Study, or National Heart, Lung, and Blood Institute.
Financial Support: By the University of California, San Francisco. The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-3367.
Reproducible Research Statement:Study protocol: Not available. Statistical code: The Cardiovascular Disease Policy Model is available to interested readers who submit a 1- to 2-page research proposal and collaboration plan to Dr. Bibbins-Domingo (e-mail, firstname.lastname@example.org) and sign the Creative Commons agreement available at http://tiny.ucsf.edu/CVDpolicymodel, pending approval by the model team. Data set: Data for this study come from sources detailed in the Supplement (available at http://tiny.ucsf.edu/CVDpolicymodel). Data from the Framingham Heart Study are available following approval of research applications submitted at http://biolincc.nhlbi.nih.gov/studies/framcohort/?q=framingham for the Framingham Heart Study cohort and http://biolincc.nhlbi.nih.gov/studies/framoffspring/?q=framingham for the Framingham Offspring Study. Data on the health survey, vital statistics, and health care costs are publicly available from government sources described in the Supplement (available at http://tiny.ucsf.edu/CVDpolicymodel).
Kazi DS, Penko J, Ollendorf DA, Coxson PG, Bibbins-Domingo K. Effect of Money-Back Guarantees on the Cost-Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors. Ann Intern Med. 2018;168:896–898. doi: 10.7326/M17-3367
Download citation file:
Published: Ann Intern Med. 2018;168(12):896-898.
Published at www.annals.org on 3 April 2018
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use